Clinical Drug Development for the Treatment of Pulmonary Arterial Hypertension: Collaboration With the Pharmaceutical Industry and Regulatory Agencies

Advances in Pulmonary Hypertension
doi 10.21693/1933-088x-9.4.214
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pulmonary Hypertension Association

Related search

A Pharmaceutical Formulation and Evaluation of a Cardiovascular Drug for Improving Pulmonary Arterial Hypertension

International Journal of Biology, Pharmacy and Allied Sciences
2018English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Adenosine Receptors as Drug Targets for Treatment of Pulmonary Arterial Hypertension

Frontiers in Pharmacology
Pharmacology
2017English

Tadalafil: The Evidence for Its Clinical Potential in the Treatment of Pulmonary Arterial Hypertension

Core Evidence
MedicineReviewsReferencesPharmacology
2007English

Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2009English

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Improving Outcomes

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2013English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

Riociguat Is a Novel Medication for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Medical Council
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy